Tyrosinase (TYR) catalyses the two initial steps of melanin synthesis from tyrosine and is a target in developing therapeutics to treat melanin-associated disorders. Here, the authors devise a TYR-based in situ catalytic platform that can generate drugs intracellularly through an endogenous copper-catalysed azide-alkyne cycloaddition reaction, as well as a TYR-catalysed in situ formed proteolysis-targeting chimeras to degrade intracellular TYR protein and decrease melanin synthesis for treating hyperpigmentation.
- Yawen You
- Zhaochen Guo
- Quanyin Hu